Drug interactions involving therapeutic radiopharmaceuticals: a systematic review
Drug interactions with therapeutic radiopharmaceuticals remain underreported, yet they may have significant clinical consequences. Clinical radiopharmacy plays a key role in detecting and preventing these interactions. Radiopharmacists, through their expertise, can identify potential interactions, influence therapeutic decisions, and positively impact patient management. Their involvement throughout the care pathway is essential to ensure the safe and effective use of these innovative therapies. Nuclear medicine physicians should also be aware that such interactions can alter biodistribution, compromise therapeutic efficacy, and increase the risk of adverse effects.
Authors
- Anthime Flaus (ORCID: https://orcid.org/0000-0001-5877-2159)
- Elise Levigoureux (ORCID: https://orcid.org/0000-0003-1231-1036)
- C. Bolot (ORCID: https://orcid.org/0000-0003-1186-0324)
- Sarah Chaïb (ORCID: https://orcid.org/0000-0001-5874-6858)
- Nina Ranjit
- M Gallet (ORCID: https://orcid.org/0000-0002-1275-9108)
- Romane Chapuis (ORCID: https://orcid.org/0009-0002-7322-0242)
- R. Gacon
- Luca Fabris-Davet
- Laurent Bourguignon
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Hôpital de la Croix-Rousse (FR)
- Centre Georges François Leclerc (FR)
- Hospices Civils de Lyon (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Laboratoire de Biométrie et Biologie Evolutive (FR)
- Hôpital Louis Pradel (FR)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1186/s41181-025-00395-y
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00